59.22MMarket Cap-696P/E (TTM)
0.950High0.880Low322.54KVolume0.950Open0.890Pre Close291.40KTurnover1.16%Turnover RatioLossP/E (Static)65.88MShares2.09852wk High0.82P/B25.03MFloat Cap0.66052wk Low--Dividend TTM27.84MShs Float17.880Historical High--Div YieldTTM7.87%Amplitude0.660Historical Low0.903Avg Price1Lot Size
IO Biotech Stock Forum
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study
IO Biotech announced promising Phase 2 results for its cancer vaccine IO102-IO103 combined with KEYTRUDA® in first-line metastatic lung cancer treatment. The study showed a 55% unconfirmed/48% confirmed overall response rate and 8...
loading...
No comment yet